

# Xiupeng Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/417541/publications.pdf>

Version: 2024-02-01

10  
papers

246  
citations

1163117

8  
h-index

1372567

10  
g-index

10  
all docs

10  
docs citations

10  
times ranked

303  
citing authors

#	ARTICLE	IF	CITATIONS
1	WWC3 regulates the Wnt and Hippo pathways via Dishevelled proteins and large tumour suppressor 1, to suppress lung cancer invasion and metastasis. <i>Journal of Pathology</i> , 2017, 242, 435-447.	4.5	57
2	Cytosolic TMEM88 Promotes Invasion and Metastasis in Lung Cancer Cells by Binding DVLS. <i>Cancer Research</i> , 2015, 75, 4527-4537.	0.9	53
3	WWC3 inhibits epithelial&ndash;mesenchymal transition of lung cancer by activating Hippo-YAP signaling. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2581-2591.	2.0	29
4	Cytosolic TMEM88 promotes triple-negative breast cancer by interacting with Dvl. <i>Oncotarget</i> , 2015, 6, 25034-25045.	1.8	27
5	ARHGEF39 promotes tumor progression via activation of Rac1/P38 MAPK/ATF2 signaling and predicts poor prognosis in non-small cell lung cancer patients. <i>Laboratory Investigation</i> , 2018, 98, 670-681.	3.7	23
6	TMEM17 promotes malignant progression of breast cancer via AKT/GSK3&beta; signaling. <i>Cancer Management and Research</i> , 2018, Volume 10, 2419-2428.	1.9	19
7	TMEM17 depresses invasion and metastasis in lung cancer cells via ERK signaling pathway. <i>Oncotarget</i> , 2017, 8, 70685-70694.	1.8	14
8	&p&gt;FAM110B Inhibits Non-Small Cell Lung Cancer Cell Proliferation and Invasion Through Inactivating Wnt/β-Catenin Signaling&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 4373-4384.	2.0	9
9	WBP2 negatively regulates the Hippo pathway by competitively binding to WWC3 with LATS1 to promote non-small cell lung cancer progression. <i>Cell Death and Disease</i> , 2021, 12, 384.	6.3	9
10	<p>FAM163A, a positive regulator of ERK signaling pathway, interacts with 14-3-3β and promotes cell proliferation in squamous cell lung carcinoma</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6393-6406.	2.0	6